Compare SQM & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQM | RDY |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | Chile | India |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 11.6B |
| IPO Year | 1993 | N/A |
| Metric | SQM | RDY |
|---|---|---|
| Price | $61.39 | $14.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $50.81 | $16.90 |
| AVG Volume (30 Days) | ★ 2.1M | 938.9K |
| Earning Date | 11-18-2025 | 01-22-2026 |
| Dividend Yield | ★ 3.45% | 0.50% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 1.84 | 0.79 |
| Revenue | ★ $4,326,111,000.00 | $3,851,623,984.00 |
| Revenue This Year | N/A | $6.16 |
| Revenue Next Year | $22.11 | $2.57 |
| P/E Ratio | $33.36 | ★ $17.87 |
| Revenue Growth | N/A | ★ 14.10 |
| 52 Week Low | $29.36 | $12.26 |
| 52 Week High | $65.65 | $16.17 |
| Indicator | SQM | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 57.67 |
| Support Level | $59.97 | $13.64 |
| Resistance Level | $65.65 | $14.20 |
| Average True Range (ATR) | 2.39 | 0.16 |
| MACD | -0.26 | 0.05 |
| Stochastic Oscillator | 48.65 | 98.25 |
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.